Clinical Trials Browser

Phase 2 × Unknown × aflutinib × Clear all

NCT06339242 2024-04-01

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Phase 2 Unknown

NSCLC

NCT05987826 2023-08-14

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05813522 2023-04-14

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04895930 2023-01-06

FOCUS-A

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05548348 2022-09-21

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05255406 2022-08-04

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05165355 2022-01-18

ATHEM

Phase 2 Unknown

NSCLC

NCT04982900 2021-10-05

TERMGGO

Phase 2 Unknown

Multiple Primary Lung Cancers

NCT04970693 2021-07-21

A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung